DENTSPLY SIRONA (NASDAQ:XRAY) Issues FY 2026 Earnings Guidance

Key Points

• FY 2026 guidance: DENTSPLY SIRONA issued EPS guidance of 1.40–1.50 (consensus 1.43) and revenue guidance of $3.5–$3.6 billion (consensus $3.6 billion), roughly in line with but slightly below street revenue expectations.
• Latest quarter showed EPS of $0.27 (missed $0.28) while revenue beat at $880 million, and the stock traded at $11.37 with a market cap of $2.28 billion and a 52-week range of $9.85–$17.18.
• Analysts are mixed with a consensus rating of Hold and an average target of $13.91, while insiders bought about 70,000 shares in the last 90 days and institutional investors own roughly 95.7% of the stock.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 1.400-1.500 for the period, compared to the consensus EPS estimate of 1.430. The company issued revenue guidance of $3.5 billion-$3.6 billion, compared to the consensus revenue estimate of $3.6 billion.

Analysts Set New Price Targets

Several research firms have recently commented on XRAY. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of DENTSPLY SIRONA in a research note on Monday, April 20th. Barrington Research increased their target price on DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an "outperform" rating in a research report on Monday, March 2nd. Robert W. Baird increased their target price on DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a "neutral" rating in a research report on Friday, February 27th. Wells Fargo & Company increased their target price on DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an "equal weight" rating in a research report on Friday, February 27th. Finally, Mizuho increased their target price on DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a "neutral" rating in a research report on Monday, March 2nd. Three investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $13.91.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ:XRAY traded up $0.17 during trading on Tuesday, hitting $11.37. 9,456,053 shares of the company's stock were exchanged, compared to its average volume of 4,456,731. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.51 and a quick ratio of 1.03. DENTSPLY SIRONA has a 52-week low of $9.85 and a 52-week high of $17.18. The business's 50-day simple moving average is $12.16 and its 200 day simple moving average is $12.03. The company has a market cap of $2.28 billion, a price-to-earnings ratio of -3.79, a PEG ratio of 1.39 and a beta of 0.93.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last released its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The business had revenue of $880.00 million for the quarter, compared to analysts' expectations of $841.80 million. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities analysts predict that DENTSPLY SIRONA will post 1.43 EPS for the current year.

Insider Activity at DENTSPLY SIRONA

In other news, Director Gregory T. Lucier purchased 27,555 shares of the business's stock in a transaction on Monday, March 2nd. The stock was acquired at an average price of $14.24 per share, for a total transaction of $392,383.20. Following the acquisition, the director directly owned 27,555 shares of the company's stock, valued at $392,383.20. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James D. Forbes purchased 5,000 shares of the business's stock in a transaction on Monday, March 9th. The shares were purchased at an average price of $12.48 per share, with a total value of $62,400.00. Following the acquisition, the director directly owned 10,000 shares in the company, valued at $124,800. This represents a 100.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 70,000 shares of company stock valued at $956,437 in the last 90 days. 0.52% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On DENTSPLY SIRONA

Several institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its holdings in DENTSPLY SIRONA by 109.8% during the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier's stock valued at $211,470,000 after buying an additional 6,970,086 shares in the last quarter. Lazard Asset Management LLC grew its holdings in DENTSPLY SIRONA by 0.9% during the 3rd quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier's stock valued at $129,445,000 after buying an additional 92,868 shares in the last quarter. State Street Corp grew its holdings in DENTSPLY SIRONA by 5.5% during the 2nd quarter. State Street Corp now owns 7,099,906 shares of the medical instruments supplier's stock valued at $113,868,000 after buying an additional 369,876 shares in the last quarter. Armistice Capital LLC grew its holdings in DENTSPLY SIRONA by 1,044.0% during the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier's stock valued at $72,790,000 after buying an additional 5,234,587 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its holdings in DENTSPLY SIRONA by 662.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier's stock valued at $58,480,000 after buying an additional 4,003,606 shares in the last quarter. Hedge funds and other institutional investors own 95.70% of the company's stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.